Enovis (ENOV) has drawn fresh attention after appointing Oliver Engert as Chief Administrative Officer, a new executive role that places him in charge of company-wide strategy, organizational efficiency and operational excellence.

The appointment of a new Chief Administrative Officer comes after a tough stretch for shareholders, with a 1 year total shareholder return decline of 44.89% and a 3 year total shareholder return decline of 57.42%, while the 90 day share price return decline of 20.94% suggests momentum has been fading ahead of Enovis’ upcoming appearance at the J.P. Morgan Healthcare Conference, where investors may look for clearer signs on execution and risk.

If executive changes at Enovis have caught your eye, it could be a good moment to widen the lens and look at other healthcare stocks that may fit your watchlist.

With the share price under pressure, a value score of 6 and an indicated 63% intrinsic discount, is Enovis now trading below what the business might be worth, or is the market already factoring in any future growth?

Most Popular Narrative: 45.7% Undervalued

With Enovis closing at US$24.66 against a narrative fair value of about US$45.45, the valuation hinges heavily on future earnings power and a higher assumed multiple.

Operational excellence initiatives including adoption of a disciplined business system (EGX), targeted resource allocation, and optimization of manufacturing and supply chain are driving ongoing gross margin expansion and improved free cash flow conversion, supporting improved earnings and deleveraging despite near term headwinds (e.g. tariffs).

Curious how modest revenue assumptions, a sharp margin reset and a very large future P/E multiple combine into that fair value? The narrative pulls these levers aggressively. The full story is all in the numbers.

Result: Fair Value of $45.45 (UNDERVALUED)

However, the story only holds if Enovis can smooth out acquisition integration and avoid further pressure from tariffs and regulatory costs that could squeeze margins again.

Build Your Own Enovis Narrative

If that story does not quite fit how you see Enovis, you can pull up the same numbers, test your own assumptions, and Do it your way in just a few minutes.

A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding Enovis.

Ready for more stock ideas?

If Enovis is on your radar, do not stop there. Broaden your watchlist with fresh ideas that match different styles and goals using the Simply Wall St Screener.

• Target potential value opportunities by scanning these 886 undervalued stocks based on cash flows where prices and cash flows are put side by side.
• Tap into the AI trend through these 25 AI penny stocks and see which companies are tying their growth stories to artificial intelligence.
• Strengthen your income focus with these 13 dividend stocks with yields > 3% and quickly spot companies offering yields above 3%.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.